The use of slow acting anti-rheumatic drugs (SAARDs) in patients with rheumatoid arthritis (RA) is often limited by lack of response or by side-effects.' 2 Combinations of SAARDs are increasingly being used where a single agent is ineffective or as an intensive first line approach to the treatment of RA,3 although the toxicity of combination therapy is uncertain. Life-table analysis of treatment episode duration allows an assessment of the probability of continuing therapy and provides important information about the clinical utility of SAARD treatment.2 4 We studied the reasons for cessation of combination therapy with methotrexate (MTX) and sulphasalazine (SSZ) in patients wth RA, and report a life-table analysis of treatment episodes.
All patients with RA (American College of Rheumatology classification criteria5) managed in a single community based rheumatology practice (GOL), who received combined MTX and SSZ treatment over five years, were studied. There were 29 patients (22 females: seven males) with a mean age of 56-7 years (range 32-76) and disease duration of 11-6 years (range 1-38).
Cessation of therapy was arbitrarily defined if MTX was discontinued for more than one month or SSZ for more than two weeks. Restarting combination therapy was considered a new treatment episode. KaplanMeier survival curves were generated from the starting and cessation dates of treatment episodes. Causes of therapy cessation were classified as: 1) inefficacy, 2) toxicity, and 3) other. All patients started combination therapy because single agents were ineffective.
There were 31 treatment episodes in 29 patients with a mean number of previous SAARDs used of 2-7 (range 1-6). MTX was used initially in 15 patients (median 7-8 months, range 3-30) and SSZ in 16 patients (median 9-4 months, range Ten treatment cessations occurred, seven due to inefficacy, one due to toxicity (severe nausea) and two others. Cessations for inefficacy occurred between three and eighteen months. The single cessation due to toxicity occurred in a patient in whom MTX was added to SSZ. Combination therapy was restarted six months later and was tolerated (follow up 3-6 months). Kaplan-Meier survival curves demonstrated a cumulative probability of continuing combination therapy of 80% and 62% at 12 and 24 months respectively (figure).
Laboratory investigations revealed macrocytosis (MCV> 100 fL) in one patient receiving MTX before combination therapy. Interestingly, Nicky's general psychological health was below average five days before setting off, presumably associated with last minute stresses. Also, using a cybex isokinetic machine to measure hamstring and quadriceps strength, power and endurance, a 5% reduction in quadriceps endurance was found at the end of the walk. This may represent early muscle damage, resulting from the calorie imbalance that invariably occurs on walking in these conditions. Furthermore, an increase in the overall T
